These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35216385)

  • 21. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
    Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
    Miller AL; Fehling SC; Garcia PL; Gamblin TL; Council LN; van Waardenburg RCAM; Yang ES; Bradner JE; Yoon KJ
    EBioMedicine; 2019 Jun; 44():419-430. PubMed ID: 31126889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.
    Karnak D; Engelke CG; Parsels LA; Kausar T; Wei D; Robertson JR; Marsh KB; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
    Clin Cancer Res; 2014 Oct; 20(19):5085-96. PubMed ID: 25117293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer.
    Wang SP; Li Y; Huang SH; Wu SQ; Gao LL; Sun Q; Lin QW; Huang L; Meng LQ; Zou Y; Zhu QH; Xu YG
    J Med Chem; 2021 Dec; 64(23):17413-17435. PubMed ID: 34813314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
    Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE
    DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
    Sen T; Tong P; Stewart CA; Cristea S; Valliani A; Shames DS; Redwood AB; Fan YH; Li L; Glisson BS; Minna JD; Sage J; Gibbons DL; Piwnica-Worms H; Heymach JV; Wang J; Byers LA
    Cancer Res; 2017 Jul; 77(14):3870-3884. PubMed ID: 28490518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
    Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
    J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
    Gilardini Montani MS; Granato M; Santoni C; Del Porto P; Merendino N; D'Orazi G; Faggioni A; Cirone M
    Cell Oncol (Dordr); 2017 Apr; 40(2):167-180. PubMed ID: 28160167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines.
    Miyamoto K; Minegaki T; Tanahashi M; Yamamoto A; Moriyama Y; Wada A; Matsumoto A; Ota K; Tanaka M; Masuda U; Tsujimoto M; Nishiguchi K
    Anticancer Res; 2019 Apr; 39(4):1813-1820. PubMed ID: 30952721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor.
    Drzewiecka M; Gajos-Michniewicz A; Hoser G; Jaśniak D; Barszczewska-Pietraszek G; Sitarek P; Czarny P; Piekarski J; Radek M; Czyż M; Skorski T; Śliwiński T
    Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
    Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An
    Myers SH; Poppi L; Rinaldi F; Veronesi M; Ciamarone A; Previtali V; Bagnolini G; Schipani F; Ortega Martínez JA; Girotto S; Di Stefano G; Farabegoli F; Walsh N; De Franco F; Roberti M; Cavalli A
    Eur J Med Chem; 2024 Feb; 265():116114. PubMed ID: 38194775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.
    Park HJ; Bae JS; Kim KM; Moon YJ; Park SH; Ha SH; Hussein UK; Zhang Z; Park HS; Park BH; Moon WS; Kim JR; Jang KY
    J Exp Clin Cancer Res; 2018 May; 37(1):107. PubMed ID: 29784019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells.
    Drzewiecka M; Jaśniak D; Barszczewska-Pietraszek G; Czarny P; Kobrzycka A; Wieczorek M; Radek M; Szemraj J; Skorski T; Śliwiński T
    J Pers Med; 2023 Aug; 13(9):. PubMed ID: 37763083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer.
    Desai D; Khandwala P; Parsi M; Potdar R
    Med Oncol; 2021 Apr; 38(6):61. PubMed ID: 33891252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.
    Fraser M; Zhao H; Luoto KR; Lundin C; Coackley C; Chan N; Joshua AM; Bismar TA; Evans A; Helleday T; Bristow RG
    Clin Cancer Res; 2012 Feb; 18(4):1015-27. PubMed ID: 22114138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
    Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
    J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.